A translational immunologist who led immunology at Merck Serono, he co-founded Calypso in 2013 as a spin-out when Merck closed its Geneva site, advancing an anti-IL-15 antibody for autoimmune disease (later acquired by Novartis).
Studied at
Ecole Nationale Veterinaire de Lyon (DVM)Universite Claude Bernard, Lyon (PhD Immunology)
Before
Director of Immunology (Biologics and Immunology platform) at Merck Serono
Director of Immunology at Coley Pharmaceutical Group
Head of Experimental Medicine and Animal Models at Schering-Plough Research Institute